Related Experiment Video
Updated: Jun 19, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Topiramate in migraine prevention
1Thomas Jefferson University Hospital, Jefferson Headache Center, Gibbon Building, 111 South Eleventh Street, Philadelphia, PA 19107, USA. Stephen.Silberstein@jefferson.edu
Expert Review of Neurotherapeutics
|October 9, 2009
Summary
Topiramate effectively reduces migraine frequency and attack numbers in large clinical trials. This antiepileptic drug is a recommended first-line option for migraine prevention, especially for patients concerned about weight gain or with coexisting conditions.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine is a prevalent episodic headache disorder with complex neurological and pain modulation components.
- Antiepileptic drugs are emerging as effective treatments for migraine prevention.
- Topiramate, an antiepileptic drug, has a unique chemical structure and mechanism of action.
Purpose of the Study:
- To evaluate the efficacy and safety of topiramate as a migraine preventive agent.
- To assess the impact of topiramate on migraine frequency, duration, and acute medication use.
- To identify common adverse events associated with topiramate treatment for migraine.
Main Methods:
- The study involved large-scale, placebo-controlled, double-blind trials (MIGR-001, MIGR-002, MIGR-003).
- Participants received daily dosages of 100 mg or 200 mg of topiramate.
- Outcomes measured included reductions in migraine frequency, migraine days, and acute medication usage.
Main Results:
- Topiramate treatment (100 or 200 mg/day) significantly decreased migraine frequency and the number of migraine attacks per month.
- A notable reduction in the use of acute migraine medications was observed.
- Common adverse events included cognitive difficulties (concentration, memory), mood changes, anorexia, weight loss, and sensory disturbances.
Conclusions:
- Topiramate is an effective first-line option for migraine prevention.
- It is particularly recommended for patients experiencing overweight, weight gain concerns, epilepsy, or bipolar disorder.
- The drug offers significant benefits in reducing migraine burden and acute medication reliance.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...